Ella Lawson: Could Erythritol Harm the Brain’s Blood Vessels?
Ella Lawson, Manager of Logistics Operations at Stryker, shared a post on LinkedIn:
”A new lab study suggests that the sugar substitute Erythritol – commonly used in so-called ‘sugar-free’ or low-calorie foods – may harm the blood-brain barrier and the tiny blood vessels in the brain.
Researchers exposed human brain microvascular endothelial cells (the cells lining the brain’s smallest blood vessels) to amounts of erythritol similar to those found in a single sweetened beverage. They discovered the exposed cells produced significantly more reactive oxygen species (a sign of oxidative stress), generated less nitric oxide (a molecule that allows blood vessels to relax), produced more endothelin-1 (which constricts vessels), and showed reduced release of a key clot-dissolving enzyme. All of these changes are well-known contributors to impaired blood flow, vessel damage, and stroke risk.
While these findings are concerning, it’s important to keep in mind that the study was conducted in lab-grown cells and did not involve living humans. That means it shows a possible mechanism for harm, but does not prove that consuming erythritol at normal dietary levels will definitely cause brain vessel disease or stroke.
Researchers say more human studies are needed. In the meantime, people – especially those with risk factors for vascular or brain diseases—may want to limit the amount of erythritol they consume and consider naturally-derived alternatives like stevia or monk fruit, while focusing on whole-food approaches rather than relying on sugar substitutes.”

Stay updated with Hemostasis Today.
-
Jul 12, 2026, 17:04Marc Carrier: EPCAT III Trial at ISTH 2026 Supports Aspirin Alone for VTE Prevention After Arthroplasty
-
Jul 12, 2026, 16:15Louise St. Germain Bannon: Global Collaboration Is Key to Turning Scientific Innovation Into Better Care
-
Jul 12, 2026, 16:10Marc Carrier: Major Scientific Highlight Confirms the Safety of the YEARS Algorithm at ISTH 2026
-
Jul 12, 2026, 16:01Joseph R. Shaw: Sharing New Insights into Antithrombotic Therapy and Thrombin Generation at ISTH 2026
-
Jul 12, 2026, 15:45Nathan Connell: Key Clinical Advances in Heavy Menstrual Bleeding and Postpartum Hemorrhage from ISTH 2026
-
Jul 12, 2026, 15:40Anne-Claire Duchez: Join Us at ISTH 2026 to Discover Our Latest Research and Meet the Team
-
Jul 12, 2026, 12:30Reduced-Dose DOACs in GI Malignancies: Toward Personalized Anticoagulation
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1